Verastem, Inc. (VSTM) stock
Close on Nov 12, 2026Market cap $764.36MP/E –Yield –
Verastem, Inc. reported revenue of $100.30M for the twelve months to Sep 30, 2026. At the latest close the market valued the company at $764.36M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $764.36M
- P/E ratio
- –
- Price to sales
- 7.62
- Price to book
- 75.67
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $100.30M
- Net income
- -$178.90M
- EPS, diluted
- -$1.94
- Book value per share
- $0.10
- Diluted shares
- 101M
Trading
- Next earnings
- Feb 3, 2027 (estimated, before the open)
- Previous close
- $9.09
- Open
- $8.84
- Day's range
- $8.41 – $9.12
- Volume
- 2,089,347
- Average volume (20 days)
- 3,510,027
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.37
- 52-week range
- $3.43 – $10.82
- RSI (14 days)
- 44.1
- Volatility (1 year)
- 74.2%
- Relative volume
- 0.67×
- WACC
- 11.8%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | VSTM | S&P 500 | Difference | VSTM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.3% | -2.7% | +5.0 pts | ||
| 3 months | +21.4% | -1.7% | +23.2 pts | ||
| Year to date | +9.3% | +11.9% | −2.6 pts | ||
| 1 year | -0.8% | +12.0% | −12.8 pts | ||
| 3 years | +32.3% | +78.2% | −45.9 pts | +9.8% | +21.2% |
| 5 years | -77.6% | +73.2% | −150.8 pts | -25.9% | +11.6% |
| 10 years | -43.7% | +309.6% | −353.4 pts | -5.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Verastem filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Update
- Results
About Verastem
Pharmaceutical Preparations
Verastem is a biopharmaceutical company that develops and commercializes targeted cancer therapeutics directed at the RAS/MAPK signaling pathway. The company's primary commercial offering is AVMAPKI FAKZYNJA CO-PACK, an oral combination of avutometinib and defactinib. Its clinical development pipeline also features VS-7375, an oral inhibitor under evaluation for solid tumors such as pancreatic, non-small cell lung, and colorectal cancers. Verastem provides its therapies to adult patients diagnosed with recurrent low-grade serous ovarian cancer following prior systemic treatment, serving healthcare providers, academic medical institutions, and community oncology practices through specialized distributors and pharmacies.
Company profile, executives and historyVerastem stock: common questions
What is Verastem's stock price?
VSTM closed at $8.44 on Nov 12, 2026, down 7.15% on the day. Over the past 52 weeks it traded between $3.43 and $10.82.
What is Verastem's market cap?
Verastem was worth $764.36M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is VSTM's P/E ratio?
Verastem lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.94), so it has no meaningful P/E ratio.
How much revenue does Verastem make?
Verastem reported revenue of $100.30M for the twelve months to Sep 30, 2026.
Does Verastem pay a dividend?
No. Verastem has not paid a cash dividend over the last twelve months.
When does Verastem report earnings next?
Verastem is expected to report Q4 FY2026 results on Feb 3, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has VSTM stock performed over the past year?
Including dividends, VSTM returned -0.8% over the past year, against +12.0% for the S&P 500.
How many VSTM shares are sold short?
20M shares were sold short at the latest FINRA report, 22.11% of the float, or 5.2 days of average trading volume.
Who are Verastem's competitors?
Companies most similar to Verastem by business, industry and size include KURA, RCUS, NUVB, GOSS, RIGL.
See a number that looks wrong?